Skip to main content

Table 3 Tumor response (immune related - irRC)

From: Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma

Response All patients
n = 30
No. of pts. (%)
irBOR
 irCR 1 (3)
 irPR 7 (23)
 irSD 9 (30)
 irPD 13 (43)
 irDCR 17 (57)
 irCBR 13 (43)
 irBORR 8 (27)
  1. ir immune related, BOR best overall response, CR complete response, PR partial response, SD stable disease, PD progressive disease, BORR best overall response rate, DCR disease control rate (CR + PR + SD), CBR clinical benefit rate (CR + PR + SD ≥ 24 weeks)